TY - JOUR
T1 - Pathophysiology, prevention, and treatment of medication overuse headache
AU - Diener, Hans Christoph
AU - Dodick, D.
AU - Evers, Stefan
AU - Holle, D.
AU - Jensen, Rigmor Hoejland
AU - Lipton, Richard B.
AU - Porreca, F.
AU - Silberstein, Stephen
AU - Schwedt, Todd
N1 - Publisher Copyright:
© 2019 Elsevier Ltd
PY - 2019/9
Y1 - 2019/9
N2 - Regular or frequent use of analgesics and acute antimigraine drugs can increase the frequency of headache, and induce the transition from episodic to chronic headache or medication overuse headache. The 1-year prevalence of this condition in the general population is between 1% and 2%. Medication overuse headache is more common in women and in people with comorbid depression, anxiety, and other chronic pain conditions. Treatment of medication overuse headache has three components. First, patients need education and counselling to reduce the intake of medication for acute headache attacks. Second, some patients benefit from drug withdrawal (discontinuation of the overused medication). Finally, preventive drug therapy and non-medical prevention might be necessary in patients at onset of treatment or in patients who do not respond to the first two steps. The optimal therapeutic approach requires validation in controlled trials.
AB - Regular or frequent use of analgesics and acute antimigraine drugs can increase the frequency of headache, and induce the transition from episodic to chronic headache or medication overuse headache. The 1-year prevalence of this condition in the general population is between 1% and 2%. Medication overuse headache is more common in women and in people with comorbid depression, anxiety, and other chronic pain conditions. Treatment of medication overuse headache has three components. First, patients need education and counselling to reduce the intake of medication for acute headache attacks. Second, some patients benefit from drug withdrawal (discontinuation of the overused medication). Finally, preventive drug therapy and non-medical prevention might be necessary in patients at onset of treatment or in patients who do not respond to the first two steps. The optimal therapeutic approach requires validation in controlled trials.
UR - http://www.scopus.com/inward/record.url?scp=85071349577&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85071349577&partnerID=8YFLogxK
U2 - 10.1016/S1474-4422(19)30146-2
DO - 10.1016/S1474-4422(19)30146-2
M3 - Review article
C2 - 31174999
AN - SCOPUS:85071349577
SN - 1474-4422
VL - 18
SP - 891
EP - 902
JO - The Lancet Neurology
JF - The Lancet Neurology
IS - 9
ER -